Both are weekly injections from the same family of medicines, both curb appetite, and both have transformed weight management. The short version of the comparison: Mounjaro (tirzepatide) has produced greater average weight loss in trials and is registered in Pakistan, while Ozempic (semaglutide) has the longer track record and remains an excellent medicine. The right one for you depends on your health profile, your goal and what your doctor finds at assessment.
At the clinic: Dr. Fehmida prescribes both tirzepatide (Mounjaro) and semaglutide within a supervised weight management programme in Clifton, Karachi. The full menu is on the peptide therapy page.
How they work: one hormone or two
Semaglutide mimics GLP-1, a gut hormone that reduces appetite, slows stomach emptying and improves blood sugar control. Tirzepatide does that and also activates a second hormone receptor called GIP. The dual action appears to be why tirzepatide shows stronger average results on both weight and blood sugar in clinical trials.
What the trials show
In the major obesity trials, people on high dose semaglutide lost around 15 percent of their body weight, while people on high dose tirzepatide lost around 20 percent over a similar period. A head to head trial published in 2025 confirmed the pattern, with tirzepatide ahead on average. Averages are not individuals though: plenty of patients respond beautifully to semaglutide, and tolerance matters as much as potency.
Availability in Pakistan
This is where the comparison gets practical. Tirzepatide is registered with DRAP and distributed through official channels in Pakistan. Ozempic is not reliably available through official channels here, which means much of what is sold locally arrives through unofficial imports where storage and authenticity are hard to verify. A genuine, properly stored pen is not a detail. It is the difference between a medicine and an expensive placebo.
Side effects: broadly similar
Both medicines share the same main side effects: nausea, constipation or diarrhoea and reduced appetite, mostly in the early weeks and during dose increases. Both carry the same key exclusions, including a personal or family history of medullary thyroid cancer, previous pancreatitis, and pregnancy. Neither should be bought and self dosed without screening.
So which one is right for you?
If you want the strongest average weight loss and a registered, traceable product in Pakistan, tirzepatide is usually the first conversation. If you have responded well to semaglutide before, or your profile suits it better, it remains a fine choice. The honest answer comes from an assessment, not a brand preference.
Common questions
Is Mounjaro stronger than Ozempic?
On trial averages, yes, tirzepatide produced more weight loss. Individual responses overlap, and the better medicine is the one you tolerate and sustain.
Can I switch from Ozempic to Mounjaro?
Often yes, with a planned transition managed by a doctor. Do not switch or stack doses on your own.
Are these the same as insulin?
No. They are appetite and metabolic hormones, not insulin, although they improve blood sugar control.
What happens when I stop?
Appetite returns, so the exit needs a plan: muscle preserved during the loss, habits built during treatment, and a maintenance phase agreed with your doctor rather than an abrupt stop.
This article is educational and does not replace medical advice. Brand names are referenced for identification only. Treatment decisions are made only after an in-person consultation.
Consultant Dermatologist and Laser Skin Specialist, MBBS, MCPS. Over 35 years in dermatology, five of them in Zurich, practising in Clifton, Karachi since 1999.
About Dr. Fehmida →